Co-Diagnostics Inc (CODX) — Titan Protect Analysis

CODX

Co-Diagnostics Inc

Healthcare · ·

$5.63

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$20M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.47

Based on estimated future earnings — lower means cheaper

Rev Growth

+190.3%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-151.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

HOLD

Consensus view from ? analysts covering this stock

About Co-Diagnostics Inc

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, hum

https://co-dx.com

Country: United States Employees: 115 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.512

Good returns relative to risk taken

Kelly Fraction

0.0403

Modest edge detected — smaller position warranted

Calmar Ratio

-0.585

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-57.0%

Historical annualised return based on price data

Max Drawdown

-97.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$46.50

88% below the year high

52W Low

$1.26

347% above the year low

Avg Volume

6,536,652

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-32.26

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.66

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

45.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-6,309.1%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$718,166

Total revenue over the last 12 months

Net Income

$-48,502,704

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go